Do analysts prefer SIGA or SPRO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer SIGA or SPRO?

In the previous week, Spero Therapeutics had 1 more articles in the media than Siga Technologies. MarketBeat recorded 7 mentions for Spero Therapeutics and 6 mentions for Siga Technologies. Spero Therapeutics' average media sentiment score of 1.12 beat Siga Technologies' score of 0.49 indicating that Spero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Siga Technologies 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spero Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SLGL or SPRO?

Sol-Gel Technologies currently has a consensus price target of $197.50, indicating a potential upside of 158.69%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, equities analysts plainly believe Sol-Gel Technologies is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sol-Gel Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer SLGL or SPRO?

In the previous week, Spero Therapeutics had 5 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 7 mentions for Spero Therapeutics and 2 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 1.61 beat Spero Therapeutics' score of 1.12 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Spero Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SPRO or ANTX?

Anthem has a consensus price target of $9.00, suggesting a potential upside of 47.30%. Given Anthem's stronger consensus rating and higher possible upside, analysts clearly believe Anthem is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Anthem 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts recommend SPRO or SBTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate SPRO or IMUX?

Immunic has a consensus target price of $47.57, indicating a potential upside of 187.20%. Given Immunic's stronger consensus rating and higher possible upside, analysts clearly believe Immunic is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Immunic 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.00

Is SPRO or IMUX more profitable?

Spero Therapeutics has a net margin of 24.90% compared to Immunic's net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Spero Therapeutics 24.90% 35.58% 24.95% Immunic N/A -215.85% -131.51%

Does the media favor SPRO or IMUX?

In the previous week, Spero Therapeutics and Spero Therapeutics both had 7 articles in the media. Spero Therapeutics' average media sentiment score of 1.12 beat Immunic's score of 1.01 indicating that Spero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunic 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Spero Therapeutics (SPRO) Competitors

$1.25 +0.07 (+5.46%)

As of 12:25 PM Eastern

Compare

SPRO vs. SIGA, SLGL, ANTX, SBTX, and IMUX

Should you buy Spero Therapeutics stock or one of its competitors? Spero Therapeutics's main competitors and comparable companies include Siga Technologies (SIGA), Sol-Gel Technologies (SLGL), Anthem (ANTX), Silverback Therapeutics (SBTX), and Immunic (IMUX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Spero Therapeutics compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

In the previous week, Spero Therapeutics had 1 more articles in the media than Siga Technologies. MarketBeat recorded 7 mentions for Spero Therapeutics and 6 mentions for Siga Technologies. Spero Therapeutics' average media sentiment score of 1.12 beat Siga Technologies' score of 0.49 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Siga Technologies	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spero Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

55.4% of Siga Technologies shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 2.7% of Siga Technologies shares are owned by insiders. Comparatively, 2.9% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Siga Technologies has higher revenue and earnings than Spero Therapeutics. Siga Technologies is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.20	$23.28M	-$0.05	N/A
Spero Therapeutics	$66.80M	1.09	$8.57M	$0.24	5.23

Siga Technologies has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market.

Spero Therapeutics has a net margin of 24.90% compared to Siga Technologies' net margin of -5.19%. Spero Therapeutics' return on equity of 35.58% beat Siga Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	-5.19%	-1.51%	-1.25%
Spero Therapeutics	24.90%	35.58%	24.95%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Spero Therapeutics beats Siga Technologies on 10 of the 14 factors compared between the two stocks.

How does Spero Therapeutics compare to Sol-Gel Technologies?

Sol-Gel Technologies (NASDAQ:SLGL) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Sol-Gel Technologies has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Spero Therapeutics has higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	11.06	-$6.13M	-$0.34	N/A
Spero Therapeutics	$66.80M	1.09	$8.57M	$0.24	5.23

Sol-Gel Technologies currently has a consensus price target of $197.50, indicating a potential upside of 158.69%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, equities analysts plainly believe Sol-Gel Technologies is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Spero Therapeutics has a net margin of 24.90% compared to Sol-Gel Technologies' net margin of -5.66%. Spero Therapeutics' return on equity of 35.58% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
Spero Therapeutics	24.90%	35.58%	24.95%

In the previous week, Spero Therapeutics had 5 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 7 mentions for Spero Therapeutics and 2 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 1.61 beat Spero Therapeutics' score of 1.12 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Spero Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Spero Therapeutics beats Sol-Gel Technologies on 9 of the 17 factors compared between the two stocks.

How does Spero Therapeutics compare to Anthem?

Spero Therapeutics (NASDAQ:SPRO) and Anthem (NASDAQ:ANTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 90.5% of Anthem shares are held by institutional investors. 2.9% of Spero Therapeutics shares are held by insiders. Comparatively, 22.6% of Anthem shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Anthem has a consensus price target of $9.00, suggesting a potential upside of 47.30%. Given Anthem's stronger consensus rating and higher possible upside, analysts clearly believe Anthem is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Spero Therapeutics had 5 more articles in the media than Anthem. MarketBeat recorded 7 mentions for Spero Therapeutics and 2 mentions for Anthem. Anthem's average media sentiment score of 1.48 beat Spero Therapeutics' score of 1.12 indicating that Anthem is being referred to more favorably in the news media.

Company	Overall Sentiment
Spero Therapeutics	Positive
Anthem	Positive

Spero Therapeutics has a net margin of 24.90% compared to Anthem's net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
Anthem	N/A	-55.75%	-50.23%

Spero Therapeutics has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market. Comparatively, Anthem has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market.

Spero Therapeutics has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	1.09	$8.57M	$0.24	5.23
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A

Summary

Spero Therapeutics beats Anthem on 9 of the 15 factors compared between the two stocks.

How does Spero Therapeutics compare to Silverback Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 2.9% of Spero Therapeutics shares are held by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Spero Therapeutics has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

Spero Therapeutics has higher revenue and earnings than Silverback Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	1.09	$8.57M	$0.24	5.23
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

In the previous week, Spero Therapeutics had 7 more articles in the media than Silverback Therapeutics. MarketBeat recorded 7 mentions for Spero Therapeutics and 0 mentions for Silverback Therapeutics. Spero Therapeutics' average media sentiment score of 1.12 beat Silverback Therapeutics' score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Spero Therapeutics	Positive
Silverback Therapeutics	Neutral

Spero Therapeutics has a net margin of 24.90% compared to Silverback Therapeutics' net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Summary

Spero Therapeutics beats Silverback Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Spero Therapeutics compare to Immunic?

Spero Therapeutics (NASDAQ:SPRO) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

In the previous week, Spero Therapeutics and Spero Therapeutics both had 7 articles in the media. Spero Therapeutics' average media sentiment score of 1.12 beat Immunic's score of 1.01 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spero Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunic	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spero Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Immunic has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Spero Therapeutics has a net margin of 24.90% compared to Immunic's net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
Immunic	N/A	-215.85%	-131.51%

Immunic has a consensus target price of $47.57, indicating a potential upside of 187.20%. Given Immunic's stronger consensus rating and higher possible upside, analysts clearly believe Immunic is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

Spero Therapeutics has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	1.09	$8.57M	$0.24	5.23
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by company insiders. Comparatively, 5.5% of Immunic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Spero Therapeutics beats Immunic on 9 of the 15 factors compared between the two stocks.

Get Spero Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRO vs. The Competition

Export

Metric	Spero Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$72.20M	$11.90B	$7.05B	$13.04B
Dividend Yield	N/A	2.70%	2.58%	10.74%
P/E Ratio	5.20	785.67	269.12	25.13
Price / Sales	1.09	933.23	643.33	105.53
Price / Cash	8.08	67.97	70.59	50.58
Price / Book	1.20	10.59	13.25	6.24
Net Income	$8.57M	$2.77B	$3.45B	$347.60M
7 Day Performance	-1.18%	0.52%	2.10%	1.71%
1 Month Performance	-42.43%	-0.19%	1.21%	0.87%
1 Year Performance	-34.97%	164.81%	67.97%	19.68%

Spero Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRO Spero Therapeutics	1.6768 of 5 stars	$1.26 +5.5%	N/A	-49.6%	$72.20M	$66.80M	5.20	150	News Coverage Positive News Earnings Report Gap Up
SIGA Siga Technologies	0.6269 of 5 stars	$3.28 +2.0%	N/A	-69.1%	$234.88M	$94.57M	12.13	40	Earnings Report Analyst Downgrade
SLGL Sol-Gel Technologies	4.0218 of 5 stars	$82.34 +0.4%	$197.50 +139.9%	+368.9%	$231.36M	$19.39M	N/A	50	News Coverage Positive News
ANTX Anthem	2.5127 of 5 stars	$5.90 +5.6%	$9.00 +52.7%	+489.7%	$212.34M	N/A	N/A	N/A	Positive News Earnings Report
SBTX Silverback Therapeutics	N/A	$5.46 +6.4%	N/A	-62.4%	$196.88M	N/A	N/A	83	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRO) was last updated on 8/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spero Therapeutics (SPRO) Competitors

SPRO vs. SIGA, SLGL, ANTX, SBTX, and IMUX

How does Spero Therapeutics compare to Siga Technologies?

Summary

How does Spero Therapeutics compare to Sol-Gel Technologies?

Summary

How does Spero Therapeutics compare to Anthem?

Summary

How does Spero Therapeutics compare to Silverback Therapeutics?

Summary

How does Spero Therapeutics compare to Immunic?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRO vs. The Competition

Spero Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spero Therapeutics (SPRO) Competitors

SPRO vs. SIGA, SLGL, ANTX, SBTX, and IMUX

How does Spero Therapeutics compare to Siga Technologies?

Does the media prefer SIGA or SPRO?

Do insiders & institutionals have more ownership in SIGA or SPRO?

Which has higher earnings and valuation, SIGA or SPRO?

Which has more volatility and risk, SIGA or SPRO?

Is SIGA or SPRO more profitable?

Do analysts prefer SIGA or SPRO?

Summary

How does Spero Therapeutics compare to Sol-Gel Technologies?

Which has more risk and volatility, SLGL or SPRO?

Do insiders and institutionals believe in SLGL or SPRO?

Which has higher valuation & earnings, SLGL or SPRO?

Do analysts recommend SLGL or SPRO?

Is SLGL or SPRO more profitable?

Does the media prefer SLGL or SPRO?

Summary

How does Spero Therapeutics compare to Anthem?

Do insiders & institutionals have more ownership in SPRO or ANTX?

Do analysts recommend SPRO or ANTX?

Does the media refer more to SPRO or ANTX?

Is SPRO or ANTX more profitable?

Which has more risk & volatility, SPRO or ANTX?

Which has higher earnings & valuation, SPRO or ANTX?

Summary

How does Spero Therapeutics compare to Silverback Therapeutics?

Do analysts recommend SPRO or SBTX?

Do insiders and institutionals have more ownership in SPRO or SBTX?

Which has more risk and volatility, SPRO or SBTX?

Which has preferable valuation & earnings, SPRO or SBTX?

Does the media refer more to SPRO or SBTX?

Is SPRO or SBTX more profitable?

Summary

How does Spero Therapeutics compare to Immunic?

Does the media favor SPRO or IMUX?

Which has more risk and volatility, SPRO or IMUX?

Is SPRO or IMUX more profitable?

Do analysts rate SPRO or IMUX?

Which has stronger earnings and valuation, SPRO or IMUX?

Do insiders & institutionals hold more shares of SPRO or IMUX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRO vs. The Competition

Spero Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools